Dipyridamole plus aspirin effectively prevented early graft occlusion after coronary-artery bypass operations compared to placebo (3% vs 10% of distal anastomoses occluded).
RCT (n=407)
double-blind
randomized
Does dipyridamole plus aspirin prevent occlusion of aortocoronary-artery-bypass grafts in patients undergoing bypass operations?
Dipyridamole and aspirin administered perioperatively effectively prevent early graft occlusion after coronary artery bypass surgery without increasing bleeding risk.
Absolute Event Rate: 3% vs 10%
To prevent occlusion of aortocoronary-artery-bypass grafts, we conducted a prospective, randomized-double-blind trial comparing dipyridamole (instituted two days before operation) plus aspirin (added seven hours after operation) with placebo in 407 patients. Vein-graft angiography was performed in 360 patients (88 per cent) within six months of operation (median, eight days). Within one month of operation, 3 per cent of vein-graft distal anastomoses (10 of 351) were occluded in the treated patients, and 10 per cent (38 of 362) in the placebo group; the proportion of patients with one or more distal anastomoses occluded was 8 per cent (10 of 130) in the treated group and 21 per cent (27 of 130) in th placebo group. This benefit in graft patency persisted in each of over 50 subgroups. Early postoperative bleeding was similar in the two groups. In this trial dipyridamole and aspirin were effective in preventing graft occlusion early after operation.
Chesebro et al. (Thu,) conducted a rct in Coronary-artery bypass operations (n=407). Dipyridamole plus aspirin vs. Placebo was evaluated on Occlusion of vein-graft distal anastomoses within one month of operation. Dipyridamole plus aspirin effectively prevented early graft occlusion after coronary-artery bypass operations compared to placebo (3% vs 10% of distal anastomoses occluded).